Advanced Biomed Inc（ADVB）の財務ADVBAdvanced Biomed Inc

Evaluating the bottom line, Advanced Biomed Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of 71.33%, provide a clear picture of how effectively ADVB converts its operational activities into shareholder value.

In the context of the broader market, ADVB competes directly with industry leaders such as TRAW and LGVN. With a market capitalization of $5.24M, it holds a significant position in the sector. When comparing efficiency, ADVB's gross margin of N/A stands against TRAW's N/A and LGVN's 63.41%. Such benchmarking helps identify whether Advanced Biomed Inc is trading at a premium or discount relative to its financial performance.

Advanced Biomed has shown inconsistent financial performance, with a net income of -$488,942 in Q3 2026 and a negative EPS of -0.38. The company did report a positive net income of $6,857,921 in Q2 2026, but this is not indicative of sustained profitability.